Century Therapeutics, Inc. Proceeds from Issuance of Common Limited Partners Units
Century Therapeutics, Inc. (IPSC) reported Proceeds from Issuance of Common Limited Partners Units of $26.81 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits · last filed 2024-03-14
- Century Therapeutics, Inc. proceeds from issuance of common limited partners units for the quarter ending 2022-12-31 was $0.00.
- Century Therapeutics, Inc. proceeds from issuance of common limited partners units for the quarter ending 2022-09-30 was $0.00.
- Century Therapeutics, Inc. proceeds from issuance of common limited partners units for the quarter ending 2022-06-30 was $0.00.
- Century Therapeutics, Inc. proceeds from issuance of common limited partners units for the quarter ending 2022-03-31 was $26.81M.
- Century Therapeutics, Inc. proceeds from issuance of common limited partners units for fiscal 2022 was $26.81M.
| Period end | Proceeds from Issuance of Common Limited Partners Units 3 month | Proceeds from Issuance of Common Limited Partners Units 6 month | Proceeds from Issuance of Common Limited Partners Units 9 month | Proceeds from Issuance of Common Limited Partners Units 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $26.81M 10-K · filed 2024-03-14 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $26.81M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $26.81M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $26.81M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |